Hosted on MSN

Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps

Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental therapy for a rare genetic condition known as Prader-Willi syndrome failed in a ...
STAT

Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Monthly Prescribing Reference

Intranasal Carbetocin Misses Endpoints in Prader-Willi Syndrome Trial

Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...
Reuters

Acadia to stop development of rare disease therapy after trial failure

Sept 24 (Reuters) - Acadia Pharmaceuticals (ACAD.O), opens new tab said on Wednesday it will discontinue development of its intranasal therapy to treat a rare genetic condition after it failed to show ...
Hosted on MSN

Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial

We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the top performers on Tuesday. Soleno Therapeutics extended its winning ...
Reuters

Soleno reports death of patient who took genetic disorder treatment, shares fall

Sept 10 (Reuters) - Soleno Therapeutics (SLNO.O), opens new tab said on Wednesday it is aware of the death of a 17 year old male who was on the company's treatment for patients who experience feelings ...